ISG15 inhibits cancer cell growth and promotes apoptosis

International Journal of Molecular Medicine

Volumn 39, Issue 2, 2017, Pages 446-452

  Zhou, Mei Juan ^a   Chen, Fang Zhi ^b   Chen, Han Chun ^a   Wan, Xin Xing ^a   Zhou, Xi ^a   Fang, Qian ^a   Zhang, Dian Zheng ^a,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

HeLa cells; HERC5; Interferon a; Interferon stimulated gene 15; P53; UBCH8; UBE1L

Indexed keywords

ALPHA INTERFERON; CASPASE 3; E1 ACTIVATING ENZYME 7; E2 CONJUGATING ENZYME; ENZYME; INTERFERON STIMULATED GENE 15; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; UBIQUITIN; UBIQUITIN LIKE MODIFIER ACTIVATING ENZYME 7; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CYTOKINE; HERC5 PROTEIN, HUMAN; ISG15 PROTEIN, HUMAN; SIGNAL PEPTIDE; UBIQUITIN PROTEIN LIGASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; PLASMID; PROTEIN EXPRESSION; PROTEIN INDUCTION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION; GENE SILENCING; GENETICS; METABOLISM; NEOPLASM; TUMOR CELL LINE;

APOPTOSIS; BIOMARKERS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HUMANS; INTERFERON-ALPHA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITINS;

EID: 85012073768     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2016.2845     Document Type: Article

References (43)

1. Duenas-Gonzalez A, Serrano-Olvera A, Cetina L and Coronel J: New molecular targets against cervical cancer. Int J Womens Health 6: 1023-1031, 2014.
2. Dasari S, Wudayagiri R and Valluru L: Cervical cancer: Biomarkers for diagnosis and treatment. Clin Chim Acta 445: 7-11, 2015.
3. Schiffman MH: Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 84: 394-398, 1992.
4. Massad LS, Turyk ME, Bitterman P and Wilbanks GD: Interferon-alpha and all-trans-retinoic acid reversibly inhibit the in vitro proliferation of cell lines derived from cervical cancers. Gynecol Oncol 60: 428-434, 1996.
5. Kim KY, Blatt L and Taylor MW: The effects of interferon on the expression of human papillomavirus oncogenes. J Gen Virol 81: 695-700, 2000.
6. Koromilas AE, Li S and Matlashewski G: Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev 12: 157-170, 2001.
7. Barnard P, Payne E and McMillan NA: The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-a. Virology 277: 411-419, 2000.
8. Lenschow DJ, Lai C, Frias-Staheli N, Giannakopoulos NV, Lutz A, Wolff T, Osiak A, Levine B, Schmidt RE, García-Sastre A, et al: IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci USA 104: 1371-1376, 2007.
9. Friedman RM: Clinical uses of interferons. Br J Clin Pharmacol 65: 158-162, 2008.
10. Sadler AJ and Williams BR: Interferon-inducible antiviral effectors. Nat Rev Immunol 8: 559-568, 2008.
11. Zhang T, Sun HC, Zhou HY, Luo JT, Zhang BL, Wang P, Wang L, Qin LX, Ren N, Ye SL, et al: Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells. Cancer Lett 290: 204-210, 2010.
12. Shi WY, Cao C and Liu L: Interferon a induces the apoptosis of cervical cancer HeLa cells by activating both the intrinsic mitochondrial pathway and endoplasmic reticulum stress-induced pathway. Int J Mol Sci 17: Pii: E1832, 2016.
13. Kim KI, Yan M, Malakhova O, Luo JK, Shen MF, Zou W, de la Torre JC and Zhang DE: Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol 26: 472-479, 2006.
14. Hishiki T, Han Q, Arimoto K, Shimotohno K, Igarashi T, Vasudevan SG, Suzuki Y and Yamamoto N: Interferon-mediated ISG15 conjugation restricts dengue virus 2 replication. Biochem Biophys Res Commun 448: 95-100, 2014.
15. Loeb KR and Haas AL: The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J Biol Chem 267: 7806-7813, 1992.
16. Haas AL, Ahrens P, Bright PM and Ankel H: Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J Biol Chem 262: 11315-11323, 1987.
17. Darb-Esfahani S, Sinn BV, Rudl M, Sehouli J, Braicu I, Dietel M and Denkert C: Interferon-stimulated gene, 15 kDa (ISG15) in ovarian high-grade serous carcinoma: Prognostic impact and link to NF-?B pathway. Int J Gynecol Pathol 33: 16-22, 2014.
18. Jeon YJ, Yoo HM and Chung CH: ISG15 and immune diseases. Biochim Biophys Acta 1802: 485-496, 2010.
19. Burks J, Reed RE and Desai SD: Free ISG15 triggers an antitumor immune response against breast cancer: A new perspective. Oncotarget 6: 7221-7231, 2015.
20. Zhao C, Hsiang TY, Kuo RL and Krug RM: ISG15 conjugation system targets the viral NS1 protein in influenza A virus-infected cells. Proc Natl Acad Sci USA 107: 2253-2258, 2010.
21. Jeon YJ, Jo MG, Yoo HM, Hong SH, Park JM, Ka SH, Oh KH, Seol JH, Jung YK and Chung CH: Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15. J Clin Invest 122: 2622-2636, 2012.
22. Wan XX, Chen HC, Khan MA, Xu AH, Yang FL, Zhang YY and Zhang DZ: ISG15 inhibits IFN-a-resistant liver cancer cell growth. BioMed Res Int 2013: 570909, 2013.
23. Strander H and Einhorn S: Interferons and the tumor cell. Biotherapy 8: 213-218, 1996.
24. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP and Pestka S: Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58: 2489-2499, 1998.
25. Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994.
26. O'Shea JJ, Gadina M and Schreiber RD: Cytokine signaling in 2002: New surprises in the Jak/Stat pathway. Cell 109 (Suppl): S121-S131, 2002.
27. Sainz B Jr, Martín B, Tatari M, Heeschen C and Guerra S: ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells. Cancer Res 74: 7309-7320, 2014.
28. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K and Taniguchi T: Integration of interferon-a/ß signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516-523, 2003.
29. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ and Zhang DE: UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 277: 9976-9981, 2002.
30. Yuan W and Krug RM: Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J 20: 362-371, 2001.
31. D'Cunha J, Knight E Jr, Haas AL, Truitt RL and Borden EC: Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci USA 93: 211-215, 1996.
32. Owhashi M, Taoka Y, Ishii K, Nakazawa S, Uemura H and Kambara H: Identification of a ubiquitin family protein as a novel neutrophil chemotactic factor. Biochem Biophys Res Commun 309: 533-539, 2003.
33. Campbell JA and Lenschow DJ: Emerging roles for immunomodulatory functions of free ISG15. J Interferon Cytokine Res 33: 728-738, 2013.
34. Desai SD, Reed RE, Burks J, Wood LM, Pullikuth AK, Haas AL, Liu LF, Breslin JW, Meiners S and Sankar S: ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood) 237: 38-49, 2012.
35. Burks J, Reed RE and Desai SD: ISGylation governs the oncogenic function of Ki-Ras in breast cancer. Oncogene 33: 794-803, 2014.
36. Kiessling A, Hogrefe C, Erb S, Bobach C, Fuessel S, Wessjohann L and Seliger B: Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene 28: 2606-2620, 2009.
37. Yoshikawa A, Imagawa A, Nakata S, Fukui K, Kuroda Y, Miyata Y, Sato Y, Hanafusa T, Matsuoka TA, Kaneto H, et al: Interferon stimulated gene 15 has an anti-apoptotic effect on MIN6 cells. Endocr J 61: 883-890, 2014.
38. Butz K, Shahabeddin L, Geisen C, Spitkovsky D, Ullmann A and Hoppe-Seyler F: Functional p53 protein in human papillo-mavirus-positive cancer cells. Oncogene 10: 927-936, 1995.
39. Mendonca MS, Howard KL, Farrington DL, Desmond LA, Temples TM, Mayhugh BM, Pink JJ and Boothman DA: Delayed apoptotic responses associated with radiation-induced neoplastic transformation of human hybrid cells. Cancer Res 59: 3972-3979, 1999.
40. Yang J, Dai LX, Chen M, Li B, Ding N, Li G, Liu YQ, Li MY, Wang BN, Shi XL and Tan HB: Inhibition of antiviral drug cidofovir on proliferation of human papillomavirus-infected cervical cancer cells. Exp Ther Med 12: 2965-2973, 2016.
41. Huang YF, Wee S, Gunaratne J, Lane DP and Bulavin DV: Isg15 controls p53 stability and functions. Cell Cycle 13: 2200-2210, 2014.
42. Huang YF and Bulavin DV: Oncogene-mediated regulation of p53 ISGylation and functions. Oncotarget 5: 5808-5818, 2014.
43. Menendez D and Anderson CW: P53 vs. ISG15: Stop, you're killing me. Cell Cycle 13: 2160-2161, 2014.